Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Short term Debt (2016 - 2024)

BioCorRx's Short term Debt history spans 8 years, with the latest figure at $1.2 million for Q3 2024.

  • For Q3 2024, Short term Debt changed N/A year-over-year to $1.2 million; the TTM value through Sep 2024 reached $1.2 million, changed N/A, while the annual FY2023 figure was $999088.0, N/A changed from the prior year.
  • Short term Debt for Q3 2024 was $1.2 million at BioCorRx, up from $865353.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $3.1 million in Q2 2022 and bottomed at $31580.0 in Q4 2021.
  • The 5-year median for Short term Debt is $2.3 million (2020), against an average of $1.8 million.
  • The largest annual shift saw Short term Debt grew 25.17% in 2020 before it crashed 98.68% in 2021.
  • A 5-year view of Short term Debt shows it stood at $2.4 million in 2020, then plummeted by 98.68% to $31580.0 in 2021, then skyrocketed by 9721.92% to $3.1 million in 2022, then plummeted by 67.79% to $999088.0 in 2023, then increased by 21.61% to $1.2 million in 2024.
  • Per Business Quant, the three most recent readings for BICX's Short term Debt are $1.2 million (Q3 2024), $865353.0 (Q2 2024), and $80190.0 (Q1 2024).